Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) for the reporting period ending March 5, 2019. The filing details the conclusion of a rights offering and the formal creation of a new series of convertible preferred stock.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $4.69 million raised from the rights offering, net of expenses.
- Securities Issued: 5,312 units sold, comprising 5,312 shares of Series B Convertible Preferred Stock and 26,560,000 warrants.
- Warrant Terms: Each warrant is exercisable for one share of Common Stock at an exercise price of $0.20 per share.
- Preferred Stock Terms: Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $0.20 per share.
- Liquidity and Debt: The filing does not provide specific data on total cash balances, existing debt obligations, or operating cash flows.
Material Changes
The primary material change is the successful completion of the rights offering, resulting in an immediate capital infusion of $4.69 million. Additionally, the company amended its capital structure by filing a Certificate of Designation to create the Series B Convertible Preferred Stock, which includes specific conversion mechanics and anti-dilution protections.
Outlook, Risks, and Management Commentary
- Conversion Mechanics: The Series B Preferred Stock is convertible at the company's option on or after March 8, 2021, or at the holder's option at any time. Conversions are subject to a 4.99% beneficial ownership limitation.
- Change of Control: In the event of a merger, consolidation, or acquisition where 50% of voting power changes hands, holders of Series B Preferred Stock have the right to receive consideration equivalent to full conversion into common stock.
- Dividends and Liquidation: Holders receive dividends on an as-if-converted basis and are entitled to liquidation proceeds pari passu with common stockholders.
- Redemption: The company is not obligated to redeem or repurchase the Series B Preferred Stock.
Investor Verification Checklist
- Verify the exact number of outstanding common shares to calculate the potential dilution from the 26,560,000 warrants and the 5,312 preferred shares.
- Confirm the current cash balance post-offering to assess runway for operations.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific exceptions to the 4.99% conversion limitation.
- Monitor the exercise price of $0.20 against the current trading price of the common stock to gauge warrant incentive.